Atwood & Palmer’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$27.4M Buy
54,746
+443
+0.8% +$213K 1.46% 32
2026
Q1
$26.7M Buy
54,303
+126
+0.2% +$68.4K 1.51% 31
2025
Q4
$31.4M Buy
54,177
+89
+0.2% +$50.3K 1.78% 25
2025
Q3
$26.2M Buy
54,088
+26
+0% +$12.1K 1.54% 28
2025
Q2
$21.9M Buy
54,062
+274
+0.5% +$115K 1.37% 31
2025
Q1
$26.8M Sell
53,788
-888
-2% -$481K 1.86% 20
2024
Q4
$28.4M Buy
54,676
+119
+0.2% +$65.4K 1.95% 19
2024
Q3
$33.7M Buy
54,557
+268
+0.5% +$159K 2.29% 16
2024
Q2
$30M Buy
54,289
+227
+0.4% +$130K 2.27% 16
2024
Q1
$31.4M Buy
54,062
+263
+0.5% +$148K 2.38% 14
2023
Q4
$28.6M Buy
53,799
+36
+0.1% +$17.4K 2.31% 14
2023
Q3
$27.2M Sell
53,763
-2,875
-5% -$1.53M 2.39% 14
2023
Q2
$29.6M Buy
56,638
+440
+0.8% +$237K 2.64% 8
2023
Q1
$32.4M Sell
56,198
-410
-0.7% -$231K 3.05% 5
2022
Q4
$31.2M Buy
56,608
+527
+0.9% +$279K 2.82% 5
2022
Q3
$28.4M Buy
56,081
+220
+0.4% +$123K 2.82% 8
2022
Q2
$30.3M Sell
55,861
-6,912
-11% -$3.8M 2.96% 5
2022
Q1
$37.1M Sell
62,773
-712
-1% -$409K 3.2% 5
2021
Q4
$42.4M Sell
63,485
-175
-0.3% -$109K 3.55% 2
2021
Q3
$36.4M Sell
63,660
-450
-0.7% -$247K 3.25% 6
2021
Q2
$32.3M Buy
64,110
+793
+1% +$374K 2.91% 6
2021
Q1
$28.9M Buy
63,317
+365
+0.6% +$174K 2.78% 10
2020
Q4
$29.3M Buy
62,952
+344
+0.5% +$161K 3.15% 4
2020
Q3
$27.6M Sell
62,608
-24,720
-28% -$10.2M 3.48% 6
2020
Q2
$31.6M Sell
87,328
-1,060
-1% -$355K 4.28% 2
2020
Q1
$25.1M Sell
88,388
-67
-0.1% -$21.1K 3.94% 3
2019
Q4
$28.7M Sell
88,455
-2,685
-3% -$814K 3.69% 4
2019
Q3
$26.5M Sell
91,140
-5,794
-6% -$1.66M 3.58% 4
2019
Q2
$28.5M Sell
96,934
-10,155
-9% -$2.8M 3.84% 5
2019
Q1
$29.3M Sell
107,089
-1,050
-1% -$261K 4.15% 4
2018
Q4
$24.2M Sell
108,139
-2,865
-3% -$672K 3.84% 5
2018
Q3
$27.1M Buy
111,004
+414
+0.4% +$95.2K 3.54% 6
2018
Q2
$22.9M Sell
110,590
-1,799
-2% -$382K 3.14% 8
2018
Q1
$23.2M Buy
112,389
+934
+0.8% +$196K 3.31% 9
2017
Q4
$21.2M Sell
111,455
-222
-0.2% -$42.5K 2.97% 11
2017
Q3
$21.1M Sell
111,677
-1,400
-1% -$254K 3.06% 13
2017
Q2
$19.7M Buy
113,077
+220
+0.2% +$37K 3.1% 10
2017
Q1
$17.3M Sell
112,857
-2,811
-2% -$430K 2.77% 14
2016
Q4
$16.3M Buy
115,668
+2,075
+2% +$306K 2.94% 13
2016
Q3
$18.1M Sell
113,593
-824
-0.7% -$127K 3.28% 8
2016
Q2
$16.9M Sell
114,417
-174
-0.2% -$25.7K 3.06% 8
2016
Q1
$16.2M Buy
114,591
+16,655
+17% +$2.23M 2.88% 10
2015
Q4
$13.9M Buy
97,936
+589
+0.6% +$78.6K 2.64% 12
2015
Q3
$11.9M Buy
97,347
+19,525
+25% +$2.54M 2.32% 16
2015
Q2
$10.1M Sell
77,822
-153
-0.2% -$19.9K 1.82% 19
2015
Q1
$10.5M Sell
77,975
-39,097
-33% -$5.04M 1.87% 20
2014
Q4
$14.7M Sell
117,072
-3,574
-3% -$435K 2.74% 7
2014
Q3
$14.7M Buy
120,646
+36,788
+44% +$4.47M 2.77% 6
2014
Q2
$9.89M Sell
83,858
-38,476
-31% -$4.53M 2.64% 6
2014
Q1
$14.7M Buy
122,334
+820
+0.7% +$97.5K 3.44% 4
2013
Q4
$13.5M Buy
121,514
+925
+0.8% +$92K 3.34% 5
2013
Q3
$11.1M Buy
120,589
+416
+0.3% +$37.6K 3.07% 11
2013
Q2
$10.2M Buy
+120,173
New +$10M 2.75% 12

Other funds holding TMO

Atwood & Palmer's TMO Position: Q2 2026 in Review

Atwood & Palmer increased its Thermo Fisher Scientific (TMO) stake by 0.82% in Q2 2026, buying an estimated $213K and bringing the position to 54,746 shares worth $27.4M. The position accounts for 1.46% of the portfolio, ranked #32.

Atwood & Palmer first reported a position in TMO in Q2 2013 and has held it in 53 quarters since. The position peaked at $42.4M in Q4 2021. 794 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Atwood & Palmer held 54,746 shares of Thermo Fisher Scientific worth $27.4M as of Q2 2026.
  • Atwood & Palmer bought 443 Thermo Fisher Scientific shares in Q2 2026, an estimated $213K.
  • Thermo Fisher Scientific made up 1.46% of Atwood & Palmer's portfolio in Q2 2026, its #32 holding.
  • Atwood & Palmer first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 53 quarters since.
  • Atwood & Palmer's Thermo Fisher Scientific position peaked at $42.4M in Q4 2021.
  • 794 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Atwood & Palmer's 13F filing for Q2 2026, filed 8 Jul 2026.